Please login to the form below

Not currently logged in
Email:
Password:

Vaccibody name Martin Bonde as CEO

He joins from EpiTherapeutics where he holds the same role

martin bonde vaccibodyNorwegian cancer vaccine company Vaccibody has appointed Dr Martin Bonde as CEO, effective from August 10.

Bonde has over 25 years of international experience in the biotech industry, starting his career at Dako and going on to work at companies including Ostemeter, Visiopharm and Aros Pharma. 

He joins from EpiTherapeutics, where he has held the role of CEO since 2009.

Tom Pike, chairman of Vaccibody, said: "We are delighted to welcome Martin Bonde to Vaccibody. The Vaccibody technology has a wide business development potential within many market segments, which will benefit greatly from Martin's extensive track record in deal making. 

“We also believe that our ability to attract an experienced industry executive with Martin's credentials reflect positively on Vaccibody's' considerable potential”.

Bonde's experience in the sector includes a number of transactions within business development, trade sales, mergers and acquisitions and management of research and development.

1st July 2015

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Pegasus

Pegasus inspires healthy decisions through creative, inspirational and integrated communications. Working with ambitious clients, we deliver big ideas and far-reaching...

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics